View in EDS HTML Full Text PDF Full Text

Interferon alfa-2b, colchicine, and benzathine penicillin versus colchicine and benzathine penicillin in Behçet's disease: a randomised trial.

Saved in:
Bibliographic Details
Title: Interferon alfa-2b, colchicine, and benzathine penicillin versus colchicine and benzathine penicillin in Behçet's disease: a randomised trial.
Authors: Demiroglu, Haluk, Ozcebe, Osman I., Barista, Ibrahim, Dundar, Semra, Eldem, Bora, Demiroglu, H (AUTHOR), Ozcebe, O I (AUTHOR), Barista, I (AUTHOR), Dündar, S (AUTHOR), Eldem, B (AUTHOR)
Source: Lancet. 2/19/2000, Vol. 355 Issue 9204, p605-609. 5p. 1 Diagram, 2 Charts, 1 Graph.
Subjects: Eye disease prevention, Behçet's disease, Therapeutic use of interferons, Vision, Patients, Physiology
Abstract: Background: Sight-threatening eye involvement is a serious complication of Behçet's disease. Extraocular complications such as arthritis, vascular occlusive disorders, mucocutaneous lesions, and central-nervous-system disease may lead to morbidity and even death. We designed a prospective study in newly diagnosed patients without previous eye disease to assess whether prevention of eye involvement and extraocular manifestations, and preservation of visual acuity are possible with combination treatments with and without interferon alfa-2b.Methods: Patients were randomly assigned 3 million units interferon alfa-2b subcutaneously every other day for the first 6 months plus 1.5 mg colchicine orally daily and 1.2 million units benzathine penicillin intramuscularly every 3 weeks (n=67), or colchicine and benzathine penicillin alone (n=68). The primary endpoint was visual-acuity loss. Analysis was by intention to treat.Findings: Significantly fewer patients who were treated with interferon had eye involvement than did patients who did not receive interferon (eight vs 27, relative risk 0.21 [95% CI 0.09-0.50], p<0.001). Ocular attack rate was 0.2 (SD 0.62) per year with interferon therapy and 1.02 (1.13) without interferon therapy (p=0.0001). Visual-acuity loss was significantly lower among patients treated with interferon than in those without interferon (two vs 13, relative risk 0.13 [95% CI 0.03-0.60], p=0.003). Arthritis episodes, vascular events, and mucocutaneous lesions were also less frequent in patients treated with interferon than in those not receiving interferon. No serious side-effects were reported.Interpretation: Therapy with interferon alfa-2b, colchicine, and benzathine penicillin seems to be an effective regimen in Behçet's disease for the prevention of recurrent eye attacks and extraocular complications, and for the protection of vision. [ABSTRACT FROM AUTHOR]
Copyright of Lancet is the property of Lancet and its content may not be copied or emailed to multiple sites without the copyright holder's express written permission. Additionally, content may not be used with any artificial intelligence tools or machine learning technologies. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)
Database: Psychology and Behavioral Sciences Collection
Full text is not displayed to guests.
FullText Links:
  – Type: pdflink
Text:
  Availability: 1
Header DbId: pbh
DbLabel: Psychology and Behavioral Sciences Collection
An: 2803589
AccessLevel: 6
PubType: Academic Journal
PubTypeId: academicJournal
PreciseRelevancyScore: 0
IllustrationInfo
Items – Name: Title
  Label: Title
  Group: Ti
  Data: Interferon alfa-2b, colchicine, and benzathine penicillin versus colchicine and benzathine penicillin in Beh&#231;et&#39;s disease: a randomised trial.
– Name: Author
  Label: Authors
  Group: Au
  Data: &lt;searchLink fieldCode=&quot;AR&quot; term=&quot;%22Demiroglu%2C+Haluk%22&quot;&gt;Demiroglu, Haluk&lt;/searchLink&gt;&lt;br /&gt;&lt;searchLink fieldCode=&quot;AR&quot; term=&quot;%22Ozcebe%2C+Osman+I%2E%22&quot;&gt;Ozcebe, Osman I.&lt;/searchLink&gt;&lt;br /&gt;&lt;searchLink fieldCode=&quot;AR&quot; term=&quot;%22Barista%2C+Ibrahim%22&quot;&gt;Barista, Ibrahim&lt;/searchLink&gt;&lt;br /&gt;&lt;searchLink fieldCode=&quot;AR&quot; term=&quot;%22Dundar%2C+Semra%22&quot;&gt;Dundar, Semra&lt;/searchLink&gt;&lt;br /&gt;&lt;searchLink fieldCode=&quot;AR&quot; term=&quot;%22Eldem%2C+Bora%22&quot;&gt;Eldem, Bora&lt;/searchLink&gt;&lt;br /&gt;&lt;searchLink fieldCode=&quot;AR&quot; term=&quot;%22Demiroglu%2C+H%22&quot;&gt;Demiroglu, H&lt;/searchLink&gt; (AUTHOR)&lt;br /&gt;&lt;searchLink fieldCode=&quot;AR&quot; term=&quot;%22Ozcebe%2C+O+I%22&quot;&gt;Ozcebe, O I&lt;/searchLink&gt; (AUTHOR)&lt;br /&gt;&lt;searchLink fieldCode=&quot;AR&quot; term=&quot;%22Barista%2C+I%22&quot;&gt;Barista, I&lt;/searchLink&gt; (AUTHOR)&lt;br /&gt;&lt;searchLink fieldCode=&quot;AR&quot; term=&quot;%22D&#252;ndar%2C+S%22&quot;&gt;D&#252;ndar, S&lt;/searchLink&gt; (AUTHOR)&lt;br /&gt;&lt;searchLink fieldCode=&quot;AR&quot; term=&quot;%22Eldem%2C+B%22&quot;&gt;Eldem, B&lt;/searchLink&gt; (AUTHOR)
– Name: TitleSource
  Label: Source
  Group: Src
  Data: &lt;searchLink fieldCode=&quot;JN&quot; term=&quot;%22Lancet%22&quot;&gt;Lancet&lt;/searchLink&gt;. 2/19/2000, Vol. 355 Issue 9204, p605-609. 5p. 1 Diagram, 2 Charts, 1 Graph.
– Name: Subject
  Label: Subjects
  Group: Su
  Data: &lt;searchLink fieldCode=&quot;DE&quot; term=&quot;%22Eye+disease+prevention%22&quot;&gt;Eye disease prevention&lt;/searchLink&gt;&lt;br /&gt;&lt;searchLink fieldCode=&quot;DE&quot; term=&quot;%22Beh&#231;et&#39;s+disease%22&quot;&gt;Beh&#231;et&#39;s disease&lt;/searchLink&gt;&lt;br /&gt;&lt;searchLink fieldCode=&quot;DE&quot; term=&quot;%22Therapeutic+use+of+interferons%22&quot;&gt;Therapeutic use of interferons&lt;/searchLink&gt;&lt;br /&gt;&lt;searchLink fieldCode=&quot;DE&quot; term=&quot;%22Vision%22&quot;&gt;Vision&lt;/searchLink&gt;&lt;br /&gt;&lt;searchLink fieldCode=&quot;DE&quot; term=&quot;%22Patients%22&quot;&gt;Patients&lt;/searchLink&gt;&lt;br /&gt;&lt;searchLink fieldCode=&quot;DE&quot; term=&quot;%22Physiology%22&quot;&gt;Physiology&lt;/searchLink&gt;
– Name: Abstract
  Label: Abstract
  Group: Ab
  Data: &lt;bold&gt;Background: &lt;/bold&gt;Sight-threatening eye involvement is a serious complication of Beh&#231;et&#39;s disease. Extraocular complications such as arthritis, vascular occlusive disorders, mucocutaneous lesions, and central-nervous-system disease may lead to morbidity and even death. We designed a prospective study in newly diagnosed patients without previous eye disease to assess whether prevention of eye involvement and extraocular manifestations, and preservation of visual acuity are possible with combination treatments with and without interferon alfa-2b.&lt;bold&gt;Methods: &lt;/bold&gt;Patients were randomly assigned 3 million units interferon alfa-2b subcutaneously every other day for the first 6 months plus 1.5 mg colchicine orally daily and 1.2 million units benzathine penicillin intramuscularly every 3 weeks (n=67), or colchicine and benzathine penicillin alone (n=68). The primary endpoint was visual-acuity loss. Analysis was by intention to treat.&lt;bold&gt;Findings: &lt;/bold&gt;Significantly fewer patients who were treated with interferon had eye involvement than did patients who did not receive interferon (eight vs 27, relative risk 0.21 [95% CI 0.09-0.50], p&lt;0.001). Ocular attack rate was 0.2 (SD 0.62) per year with interferon therapy and 1.02 (1.13) without interferon therapy (p=0.0001). Visual-acuity loss was significantly lower among patients treated with interferon than in those without interferon (two vs 13, relative risk 0.13 [95% CI 0.03-0.60], p=0.003). Arthritis episodes, vascular events, and mucocutaneous lesions were also less frequent in patients treated with interferon than in those not receiving interferon. No serious side-effects were reported.&lt;bold&gt;Interpretation: &lt;/bold&gt;Therapy with interferon alfa-2b, colchicine, and benzathine penicillin seems to be an effective regimen in Beh&#231;et&#39;s disease for the prevention of recurrent eye attacks and extraocular complications, and for the protection of vision. [ABSTRACT FROM AUTHOR]
– Name: AbstractSuppliedCopyright
  Label:
  Group: Ab
  Data: &lt;i&gt;Copyright of Lancet is the property of Lancet and its content may not be copied or emailed to multiple sites without the copyright holder&#39;s express written permission. Additionally, content may not be used with any artificial intelligence tools or machine learning technologies. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract.&lt;/i&gt; (Copyright applies to all Abstracts.)
PLink https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=pbh&AN=2803589
RecordInfo BibRecord:
  BibEntity:
    Identifiers:
      – Type: doi
        Value: 10.1016/S0140-6736(99)05131-4
    Languages:
      – Code: eng
        Text: English
    PhysicalDescription:
      Pagination:
        PageCount: 5
        StartPage: 605
    Subjects:
      – SubjectFull: Eye disease prevention
        Type: general
      – SubjectFull: Behçet's disease
        Type: general
      – SubjectFull: Therapeutic use of interferons
        Type: general
      – SubjectFull: Vision
        Type: general
      – SubjectFull: Patients
        Type: general
      – SubjectFull: Physiology
        Type: general
    Titles:
      – TitleFull: Interferon alfa-2b, colchicine, and benzathine penicillin versus colchicine and benzathine penicillin in Behçet's disease: a randomised trial.
        Type: main
  BibRelationships:
    HasContributorRelationships:
      – PersonEntity:
          Name:
            NameFull: Demiroglu, Haluk
      – PersonEntity:
          Name:
            NameFull: Ozcebe, Osman I.
      – PersonEntity:
          Name:
            NameFull: Barista, Ibrahim
      – PersonEntity:
          Name:
            NameFull: Dundar, Semra
      – PersonEntity:
          Name:
            NameFull: Eldem, Bora
      – PersonEntity:
          Name:
            NameFull: Demiroglu, H
      – PersonEntity:
          Name:
            NameFull: Ozcebe, O I
      – PersonEntity:
          Name:
            NameFull: Barista, I
      – PersonEntity:
          Name:
            NameFull: Dündar, S
      – PersonEntity:
          Name:
            NameFull: Eldem, B
    IsPartOfRelationships:
      – BibEntity:
          Dates:
            – D: 19
              M: 02
              Text: 2/19/2000
              Type: published
              Y: 2000
          Identifiers:
            – Type: issn-print
              Value: 01406736
          Numbering:
            – Type: volume
              Value: 355
            – Type: issue
              Value: 9204
          Titles:
            – TitleFull: Lancet
              Type: main
ResultId 1